Related Experiment Video
Updated: Jul 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Bridging the gap in treatment options for patients with hypertriglyceridemia
James A Underberg1, Richard Hays
1Division of General Internal Medicine, New York University Medical School, New York, NY USA.
Abstract:
Hypertriglyceridemia is a commonly encountered problem in primary care practice. In 2002, the Third National Health and Nutrition Examination Survey reported that among adults 20 years of age and older, 30% had a triglyceride (TG) level greater than 150 mg/dL, and among people 50 years of age and older, the prevalence was 42.8%. Recent data suggest that elevated TG levels are an independent risk factor for cardiovascular disease (CVD). It is important, therefore, that clinicians identify patients with hypertriglyceridemia and initiate treatment as appropriate. In this article, we use a case study to illustrate the appropriate identification and treatment of a patient at risk. We also review the etiology of hypertriglyceridemia, its association with CVD, the recommended approach to treatment, and the efficacy and tolerability of therapeutic options.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenomics: Identification of New Drug Targets
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
